Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — 24th Annual Needham Virtual Healthcare Conference 2025
16 slides from Lexicon Pharmaceuticals's conference presentation, April 2025
Slide 1: 24th Annual Needham Virtual Healthcare Conference
24th Annual Needham Virtual Healthcare Conference April 2025 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Focusing on Science And Advancing Clinical Programs
Company Overview Company Overview Focusing on Science And Advancing Clinical Programs Positioned for value creation ATTRACTIVE DEVELOPMENT LEAN, AGILE NEAR-TERM ASSETS EXPERTISE ORGANIZATION CATALYSTS • Diversified pipeline • Clinical drug • Full focus as a • Pilavapadin Ph. 2b full platform potenti
Slide 4: Focused on advancing a strong R&D pipeline
Company Overview Focused on advancing a strong R&D pipeline Announced topline data from Phase 2b dose optimization PROGRESS study of pilavapadin in DPNP Continued enrollment in pivotal Phase 3 study of sotagliflozin in SONATA-HCM Advanced IND-enabling studies of LX9851 in obesity and related metabol
Slide 5: A portfolio of potential "pipelines in a pill"
Company Overview A portfolio of potential “pipelines in a pill” 2025 2026 2027 2028 2029 Pilavapadin (LX9211) Ph3 Initiation Q1 PDUFA Approval Diabetic Peripheral Neuropathic Pain (DPNP) Ph3 planning / execution 2028 Approval Postherpetic Neuralgia (PHN) Ph2 planning / execution 2029 Approval MS Spa
Slide 6: Pilavapadin: LS Mean Change from Baseline at Week 8
Pilavapadin PROGRESS study identified 10 mg dose as most clinically meaningful and reaffirms 10 mg as most appropriate to advance into Phase 3 clinical development pilavapadin pilavapadin pilavapadin Placebo 10 mg 20 mg/10 mg* 20 mg 0 LS Mean Change from Baseline at Week 8 -1 -1.31 -1.38 -1.74 -1.70
Slide 7: Pilavapadin: post-hoc analysis of pooled 10 mg arms
Pilavapadin PROGRESS post-hoc analysis reaffirms 10 mg as most appropriate to advance into Phase 3 clinical development Efficacy of pooled, 10 mg dosing arms (post-hoc) Key Findings 0.0 • 10 mg dose demonstrated early and sustained separation LS Mean Change from Baseline -0.5 from placebo -1.0 • Pos
Slide 8: A clear need and opportunity in the DPNP treatment landscape
Pilavapadin A clear need and opportunity in the DPNP treatment landscape for new treatments Sizable Market Opportunity for DPNP High Unmet Need ~9 Low Alternatives 60% Million Satisfaction to Pain Act U.S. patients with of patients have with current physicians progressive DPNP tried multiple treatme
Slide 9: Focused on further differentiating sotagliflozin among SGLT class
Sotagliflozin Focused on further differentiating sotagliflozin among SGLT class and maintaining a scientific presence in CV 2025 Focus: Bridging strategy to potential HCM indication INPEFA remains available on the market with continued commitment to maintain awareness and provide tools to support pa
Slide 10: The Lancet Diabetes & Endocrinology highlights unique efficacy benefits of sotagliflozin
Sotagliflozin The Lancet Diabetes & Endocrinology highlights unique efficacy benefits of sotagliflozin Cumulative incidence of total MACE by treatment group 12 11.6 Placebo Sotagliflozin 10.0 9 • Reduced major adverse cardiovascular events Events (per 100 patients) (MACE), MI and stroke among patien
Slide 11: Sotagliflozin has Potential to Occupy a Unique Position in Symptomatic HCM
Sotagliflozin HCM Sotagliflozin has Potential to Occupy a Unique Position in Symptomatic HCM HCM Disease Progression and Treatment Journey First Line Severe/Obstructive Hypertrophic Continued Disease Progression Cardiomyopathy Treatment Beta Blocker (BB) +/- Sotagliflozin Opportunity Cardiac Myosin
Slide 12: LX9851 has the potential to address unmet needs in obesity
LX9851 Based on pre-clinical studies, LX9851 has the potential to address unmet needs in obesity and related cardiometabolic disorders LX9851 First in class, potent and selective orally bioavailable, investigational small molecule ACSL5 inhibitor Biology-based Mechanism to Address Obesity Potential
Slide 13: LX9851: Weight loss maintained after semaglutide discontinuation
LX9851 LX9851: Weight loss maintained after semaglutide discontinuation in HFD-fed DIO mice 52 Semaglutide Withdrawal After Initial Weight Loss 50 48 46 * * ** Body Weight (g) 44 42 * 40 38 * 36 ** *** ** 34 Control #1: PBS Semaglutide treatment withdrawn after day 14 Semaglutide (0-14); w/o (15-28)
Slide 14: Recent collaborations designed to unlock long-term value
Partnering Recent collaborations designed to unlock long-term value in areas of high opportunity Exclusive licensing agreement for LX9851 in Exclusive licensing agreement for sotagliflozin obesity and all other indications in cardiometabolic and all other indications Global markets All markets outsi
Slide 15: Significant number of planned catalysts through 2025
Conclusion Significant number of planned catalysts through 2025 Pipeline Indication Planned Catalyst 2025 • Full PROGRESS data anticipated in Q2 • Diabetic Peripheral Neuropathic • End of Phase 2 meeting planned in Q3 Pilavapadin Pain • Data at upcoming medical meetings • Partnership discussions ong
Slide 16: Thank You
Thank You pharmaceuticals
Lexicon Pharmaceuticals — 24th Annual Needham Virtual Healthcare Conference 2025 on 6ix